couldn’t that just mean that the test is most well suited to stopping disease in individuals that are considered low risk which would be a lot of type 2 diabetics? I don’t see how those two statements from NICE and MSAC are so different? The aim is to stop end stage renal failure in people who would normally be considered low risk and aren’t captured until it’s too late? Thoughts?
couldn’t that just mean that the test is most well suited to...
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.005(0.51%) |
Mkt cap ! $128.9M | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | 99.0¢ | 97.5¢ | $164.1K | 167.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17664 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 16000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
99.0¢ |
Change
0.005 ( 0.25 %) |
||||
| Open | High | Low | Volume | ||
| 98.0¢ | 99.0¢ | 97.5¢ | 48416 | ||
| Last updated 15.59pm 23/05/2024 ? | |||||
| PIQ (ASX) Chart |